AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge their drug development efforts -- and 's (NASDAQ: AZN) materials are no different.
But will using the rapidly advancing technology drive its shares to new heights or merely enable it to keep up with its competitors? Let's probe this issue by looking at the collaboration and acquisition activity that the company is pursuing.
It's no surprise that drugmakers are interested in using AI to accelerate the pace of drug development. Under normal conditions, it can take biopharmas a long time to identify promising targets for therapies and leads for molecules that can interact with those targets in a controllable and medicinal fashion in the context of the human body.
Source Fool.com
